Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ: IOVA )

3.900 +0.170 (+4.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led... 
Via Benzinga
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
The Federal Reserve's fight against inflation may soon yield financial benefits. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
How Is The Market Feeling About Iovance Biotherapeutics?
Via Benzinga
What's Going On With Iovance Biotherapeutics Today?
On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented... 
Via Benzinga
Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position. 
Via InvestorPlace
Is Iovance Biotherapeutics a Millionaire Maker?
This biotech's future is bright, but how good could it get for investors? 
Via The Motley Fool
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Is It Too Late to Buy Iovance Biotherapeutics Stock?
The stock is down more than 50% from its 52-week high. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights. 
Via InvestorPlace
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
New data indicate that its cell therapy could soon find a larger market. 
Via The Motley Fool
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets 
Via News Direct
Exposures Product Safety
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These biotech stocks have just launched their first products. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
4 Small-Cap Value Stocks That Could Go Parabolic
These four small-cap stocks scan as deeply undervalued right now. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
Why Iovance Stock Is Down 18% Today
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.